Clinical Evidence

Delve into clinical research studies and more

Clinical research lies at the heart of who we are. Vantive uses scientific evidence systematically, and transparently, to inform the development of new state-of-the-art solutions for patients around the world. Here you can find various studies, white papers and articles concerning important topics across the wide range of therapy areas served by Vantive.

HDx therapy enabled by the Theranova Dialyzer
Extracorporeal light-chain elimination in myeloma with simple medium cutoff membrane hemodialysis: a retrospective cohort study
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Extracorporeal Removal of Myoglobin in Patients with Rhabdomyolysis and Acute Kidney Injury: Comparison of High and Medium Cut-Off Membrane and an Adsorber Cartridge
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Extracorporeal Techniques in End-Stage Kidney Disease
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Flow Dynamic Analysis by Contrast-Enhanced Imaging Techniques of Medium Cutoff Membrane Hemodialyzer.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Fluctuations in Interleukin-6 Levels during Hemodialysis Sessions with Medium Cutoff Membranes: An Analysis on COVID-19 Case Series
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
From old uraemic toxins to new uraemic toxins: place of 'omics'
Visit resource site
PD
Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS) - Marshall J, et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Haemodialysis membranes
Visit resource site
PD
Health status and quality of life reported by incident patients after 1 year on haemodialysis or peritoneal dialysis - Kutner NG, et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
Hemodiafiltration (HDF) versus expanded hemodialysis (HDx)
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
High-Flux versus High-Retention-Onset Membranes: In vivo Small and Middle Molecules Kinetics in Convective Dialysis Modalities - Cordeiro ISF et al.
Visit resource site
HDx therapy enabled by the Theranova Dialyzer
High-volume online haemodiafiltration treatment and outcome of end-stage renal disease patients: more than one mode.
Visit resource site

Important Safety Information

INTENDED USE

The Theranova Dialyzer is indicated for patients with chronic kidney failure who are prescribed intermittent hemodialysis. It provides an expanded solute removal profile with increased removal of various middle molecules (up to 45 kDa) that may play a pathologic role in the uremic clinical syndrome. The Theranova Dialyzer is not intended for hemofiltration or hemodiafiltration therapy. The total extracorporeal blood volume for the Theranova Dialyzer and the set should represent less than 10% of the patient's blood volume.

For single use only.

 

Rx Only. For safe and proper use of the products mentioned herein, please refer to the appropriate Operator’s Manual or Instructions for Use.

 

Vantive, HDx and Theranova are trademarks of Vantive Health LLC or its affiliates.